Artikel
Silver-coated endoprosthetic replacement of the proximal humerus in case of tumour – is there an increased risk of periprosthetic infection by using a trevira tube?
Suche in Medline nach
Autoren
Veröffentlicht: | 23. Oktober 2017 |
---|
Gliederung
Text
Objectives: The aim of our study was to evaluate if there is an increased risk of periprosthetic infection (PJI) in patients following replacement of the proximal humerus by using a modular tumor prosthesis in combination with a trevira tube.
Methods: Thirty patients were treated by using a modular tumor endoprosthesis (MUTARS®) following intraarticular resection of the proximal humerus. Fifteen patients received treatment by using a trevira tube. In fifteen further cases the use of a trevira tube was not necessary. The mean follow-up time was 26 months (range: 24 months to 84 months). Both, Enneking Score and Range of Motion (ROM), was evaluated. Further radiographs were obtained in two planes.
Results and Conclusion: The survival rate one year after surgery was 83% and 63% after two years. We recorded a 96% survival of the limb two years after surgery. We also observed only one case of periprosthetic joint infection (PJI) in the entire follow-up period in one patient who received treatment with a trevira tube. The mean Enneking score was 20 points (range 8 to 26 points). ROM was equal in both study groups. In total 20% of the treated patients (n=6) suffered complications.
Replacement of the proximal humerus by using a trevira tube in combination with a modular tumor endoprosthesis is a safe and viable treatment option for both, bone tumors and metastases. There is no statistically significant increased risk of infection by using trevira tube even among immunosuppressed patients.